Search results
Results from the WOW.Com Content Network
It was used to treat symptoms associated with allergies and colds such as itchy and watery eyes, runny nose, nasal and sinus congestion, and sneezing. Because it contains pseudoephedrine, its purchase in the United States was severely restricted by the Combat Methamphetamine Epidemic Act of 2005 over fears that any product containing ...
Dexbrompheniramine is an antihistamine with anticholinergic properties [1] used to treat allergic conditions such as hay fever or urticaria. It is the pharmacologically active dextrorotatory isomer of brompheniramine. It was formerly marketed in combination with pseudoephedrine under the name Drixoral in the US and Canada. It is an alkylamine ...
Still used as veterinary drug and as a human antihelminthic in many markets; listed on the WHO List of Essential Medicines. In humans, it was used to treat melanoma before it was withdrawn for agranulocytosis. [29] [30] [31] Levomethadyl acetate: 2003 US Cardiac arrhythmias and cardiac arrest. [2] Lorcaserin (Belviq) 2020 US Increased risk of ...
Daily sales limit—must not exceed 3.6 grams of pseudoephedrine base without regard to the number of transactions; 30-day (not monthly) sales limit—must not exceed 7.5 grams of pseudoephedrine base if sold by mail order or "mobile retail vendor" 30-day purchase limit—must not exceed 9 grams of pseudoephedrine base.
Burping is often considered a "faux pas," as it can be embarrassing and off-putting, especially in social situations. But for some, the inability to belch can be an issue that can cause discomfort.
Chlorphenamine is an alkylamine and is a part of a series of antihistamines including pheniramine (Naphcon) and its halogenated derivatives including fluorpheniramine, dexchlorphenamine (Polaramine), brompheniramine (Dimetapp), dexbrompheniramine (Drixoral), deschlorpheniramine, and iodopheniramine.
Health officials in Europe are investigating Ozempic and the trendy drug’s possible link to an eye-rotting condition that causes blindness. On Dec. 17, the European Medicines Agency announced ...
Lilly answered with Mounjaro and Zepbound, approved in 2022 and 2023 for diabetes and weight loss, respectively. They use the active ingredient tirzepatide, which mimics not just GLP-1 but another ...